Edaravone Dexborneol for Blood-Brain Barrier Repair in Acute Anterior Circulation Stroke
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 432 participants.
Also called NCT07933692
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 432 participants
- Sponsor
- Registry
-
NCT07933692
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07933692. Randomized; no masking; primary purpose treatment. Start 2021-10-01 (actual); primary completion 2026-12-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Edaravone Dexborneol for Blood-Brain Barrier Repair in Acute Anterior Circulation Stroke
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Edaravone
- Intervention (Drug)
- Edaravone Dexborneol
- Lead sponsor
- Shandong Provincial Hospital
- Collaborator
- Dongying People's Hospital
- Collaborator
- Zibo Central Hospital
- Collaborator
- Heze Municipal Hospital
- Collaborator
- Shengli Oilfield Hospital
- Collaborator
- Liaocheng People's Hospital
- Collaborator
- Tengzhou Central People's Hospital
- Collaborator
- Shandong Province Third hospital
- Collaborator
- Zaozhuang Municipal Hospital
Record details
- Record id
cardio:ct-nct07933692- Content hash
df8bc6d1e620b544e00cf2608563a7efe39cbc5d632614639070f7083c2513d3